Lachlan Mackinnon

Base Genomics is a new start-up that aims to have a major impact on personalised medicine. We are developing TAPS, a breakthrough technology from the University of Oxford that makes epigenetic analysis of DNA methylation more sensitive, accurate and cheaper than ever before. We aim to transform healthcare by enabling early and precise detection of cancer. Long-term, we expect TAPS to become central to a host of major new healthcare and research applications. *We are hiring* We are looking for talented chemists, enzymologists, protein engineers, NGS specialists, bioinformaticians and software developers at all levels. Check out the available roles at basegenomics.com/join-us

EnzBond is an innovative start-up that aims to change the current understanding of biocatalysis. Here at EnzBond we have developed an automated In Silico platform that allows rapid optimization of enzymes used for the production of small molecules. Our proprietary technology allows us to drop the enzyme discovery cost >10x compared to the current market leaders and compress the discovery time to days.

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the worlds first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

Base Genomics is a new start-up that aims to have a major impact on personalised medicine. We are developing TAPS, a breakthrough technology from the University of Oxford that makes epigenetic analysis of DNA methylation more sensitive, accurate and cheaper than ever before. We aim to transform healthcare by enabling early and precise detection of cancer. Long-term, we expect TAPS to become central to a host of major new healthcare and research applications. *We are hiring* We are looking for talented chemists, enzymologists, protein engineers, NGS specialists, bioinformaticians and software developers at all levels. Check out the available roles at basegenomics.com/join-us

EnzBond is an innovative start-up that aims to change the current understanding of biocatalysis. Here at EnzBond we have developed an automated In Silico platform that allows rapid optimization of enzymes used for the production of small molecules. Our proprietary technology allows us to drop the enzyme discovery cost >10x compared to the current market leaders and compress the discovery time to days.

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.